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ABSTRACT
Cleft lip with or without cleft palate (CL/P) is a common human birth defect whose etiologies remain
largely unknown. Several studies have demonstrated that periconceptional supplementation of folic
acid can reduce risk of CL/P in offspring. In this study, we tested the hypothesis that the preventive
effect of folic acid is manifested through epigenetic modifications by determining whether DNA
methylation changes are associated with CL/P. To more readily observe the potential effects of
maternal folate on the offspring epigenome, we focused on births prior to mandatory dietary folate
fortification in the United States (i.e. birth year 1997 or earlier). Genomic DNA methylation levels
were assessed from archived newborn bloodspots in a 182-member case-control study using the
Illumina® Human Beadchip 450K array. CL/P cases displayed striking epigenome-wide hypomethyla-
tion relative to controls: 63% of CpGs interrogated had lower methylation levels in case newborns,
a trend which held up in racially stratified sub-groups. 28 CpG sites reached epigenome-wide
significance and all were case-hypomethylated. The most significant CL/P-associated differentially
methylated region encompassed the VTRNA2-1 gene, which was also hypomethylated in cases
(FWER p = 0.014). This region has been previously characterized as a nutritionally-responsive,
metastable epiallele and CL/P-associated methylation changes, in general, were greater at or near
putative metastable epiallelic regions. Gene Set Enrichment Analysis of CL/P-associated DMRs
showed an over-representation of genes involved in palate development such as WNT9B, MIR140
and LHX8. CL/P-associated DNA methylation changes may partly explain the mechanism by which
orofacial clefts are responsive to maternal folate levels.
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Introduction
Although their etiologies are largely unknown,
isolated orofacial clefts are suspected of being etio-
logically heterogeneous with both genetic and
non-genetic risk factors [1]. Clinical observations
have indicated that isolated orofacial clefts should
be classified into at least two distinct phenotypic
groups: cleft lip with or without cleft palate (CL/
P), and cleft palate alone (CPO) [2]. Collectively,
these are among the most common birth defects
with a worldwide prevalence of approximately 1 in
700 live births [3].
Genetic associations for CL/P have been observed
for both common and rare variants in numerous
genes from either linkage analysis, candidate gene,
or genome-wide association studies [e.g. see 1,4,5].
The relatively large number of associated loci is
probably indicative of the complex genetic etiologies
underlying the CL/P phenotype and explain only
a fraction of the population burden of these human
birth defects. Several non-genetic factors also con-
tribute to cleft phenotypes [6]. Of particular rele-
vance to this study, maternal use of multivitamin
supplements containing folic acid in early pregnancy
has been associated with decreased risk of CL/P
[7,8]. Although there are reports of no such reduc-
tion in risk [see ref. 9], the benefit of periconcep-
tional folic acid has been reinforced in subsequent
meta-analyses [10,11].
CONTACT Nicholas J. Marini nmarini@berkeley.edu 324 Stanley Hall California Institute for Quantitative Biosciences University of California Berkeley, CA 94720
Supplementary data for this article can be accesed here.
EPIGENETICS
2019, VOL. 14, NO. 2, 198–213
https://doi.org/10.1080/15592294.2019.1581591
© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
The underlying mechanisms by which folic acid
may reduce CL/P risks are unknown. The essen-
tial role of folate-dependent reactions in the
synthesis of the cellular methyl group donor
S-adenosylmethionine (AdoMet) has pointed to
epigenetic alterations (DNA and histone methyla-
tion). Several observations support this hypoth-
esis. First, multiple studies suggest a critical role
for DNA methylation changes in normal murine
palatogenesis [12,13] as well as in murine models
of isolated orofacial clefts [14,15]. Second, like
folate, increased maternal intake of choline has
been associated with decreased CL/P risk [16].
The conversion of choline to glycine is a second
route toward AdoMet synthesis and metabolic
imbalances as well as genetic variation in this
pathway have been associated with CL/P [5,17].
Thus, more than one nutrient affecting methyl
donor status has been associated with CL/P.
Third, the critical period for reduction of risk by
periconceptional supplementation of folate and/
or choline coincides with the reprogramming of
the fetal epigenome in early embryogenesis
[18,19]. Indeed, some epigenomic regions (the
so-called Metastable Epialleles), are particularly
sensitive to maternal nutritional status around
the time of conception and, thus, display inter-
individually variable levels of DNA methylation
[20-22]. These regions are more likely to be asso-
ciated with enhancers or transcription start sites
and so may be enriched for epigenetic changes
with functional consequence [21].
More directly, some reports have demonstrated
DNA methylation changes associated with orofa-
cial clefts in humans [23,24]. Sharp et al [23]
described differentially methylated regions that
may be characteristic for different subtypes of
clefts (e.g. isolated cleft palate vs. cleft palate with
cleft lip). Alvizi et al [24] described methylation
changes at individual CpGs from a CL/P case-
control study and suggested that DNA methyla-
tion changes may interact with genetic risk factors
to increase penetrance. However, the relevance of
these sites to metastable epiallelic regions in the
epigenome is not yet known.
In this report, we further evaluated maternal folic
acid status in fetal epigenetic modifications relevant to
orofacial clefts by examining DNA methylation
changes in a CL/P case-control study. However, we
restricted our analysis to only births prior to manda-
tory dietary folate fortification in the United States.
We imposed this criterion with the rationale that, by
eliminating the global epigenomic impact of folate
fortification, nutrient-sensitive epigenomic differ-
ences between CL/P cases and controls would be
more easily observable.We found that CL/P case new-
borns frompre-fortification births displayed a striking
epigenome-wide trend toward hypomethylation.
Moreover, the most extensive case-associated methy-
lation changes occurred at or near putative metastable
epialleles. CL/P-associated differentially methylated
regions implicated genes previously known to be
involved in orofacial clefts and/or palatogenesis.
Results
This study evaluated the extent to which epialleles of
CpG dinucleotides might account for the well-
established ability of folate supplementation to reduce
risk of isolated CL/P. Seventy-four Hispanic and 20
non-Hispanic white neonates with CL/P were
included, as well as 69 Hispanic and 19 non-
Hispanic white nonmalformed controls (Table 1).
The distribution of other clinical variables (e.g. mater-
nal age, gestational age, birth weight, etc.) was com-
parable between ethnic groups and between cases and
controls. The most noteworthy feature of the sample
population was that all bloodspots used for analysis
were collected from newborns born prior to manda-
tory dietary fortification of folic acid in the United
States (birth years 1997 or earlier). We imposed this
criteria hypothesizing that doing so would allow us to
more easily observe folate (or other nutrient)-sensitive
epigenomic differences between CL/P cases and con-
trols should they exist.
Table 1. Study population.
Race/Ethnicity Sex
Cases
(Collective
Percentage)
Controls
(Collective
Percentage)
White, Hispanic M 44 (46.8) 42 (47.7)
F 30 (31.9) 27 (30.7)
White, non-Hispanic M 13 (13.8) 9 (10.2)
F 7 (7.4) 10 (11.4)
TOTAL 94 88
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Widespread hypomethylation effects
We observed a fairly extensive CL/P-associated hypo-
methylation across the epigenomic profile. Out of the
319,253 CpGs queried on the array (after applying
filters), 202,672 (63.5%) displayed a negative regres-
sion coefficient (indicating a lower methylation level
in cases) in the entire population (Figure 1).
Furthermore, the most significantly changing CpGs
(lowest p value) were almost exclusively hypomethy-
lated. Stratification of the sample population by ethni-
city showed a nearly identical phenomenon in both
sub-group populations. Case hypomethylation was
observed formostCpGs inHispanic (61.2%) andnon-
Hispanic white (61.5%) newborns.
The significance of this hypomethylation profile
was further supported by the high degree of con-
cordance observed between Hispanic and non-
Hispanic white subgroups with respect to the direc-
tionality of case-associated changes. The subset of
CpG sites with nominally significant changes
(p < 0.05 or p < 0.01) in both ethnic subgroups
were strikingly concordant (χ2 p < 1E-30) and
heavily biased toward hypomethylation (Figure 2).
Indeed, there was substantial concordance through-
out the profiles even for the many CpG sites that
did not reach statistical significance in either sub-
group (Fig. S1). These data indicate that, despite
sample size and ethnicity difference, methylation
signatures for these subgroups were similar and
that widespread hypomethylation is related to the
CL/P phenotype. Thus, in most subsequent ana-
lyses, we combined both ethnic sub-groups to
enhance statistical power, while potentially mitigat-
ing any confounding from ethnically-sensitive
positions. Summary statistics for all 319,253 CpG
sites in the combined population and ethnically-
stratified sub-groups are in supplementary Tables
S1-S3.
EWAS analysis
Twenty-eight individual CpGs reached genome-
wide significance for methylation changes
(Bonferroni cut-off p = 1.57E-07) when con-
sidering all samples (Table 2, Fig. S3).
Interestingly, all 28 CpG positions were hypo-
methylated in cases. This directionality was
also seen in Hispanic and non-Hispanic white
cases when these subgroups were analyzed
separately (not shown). While most of these
sites were closely associated with a gene, there
was no statistically significant enrichment of
functional elements (e.g. DNaseI hypersensitive
sites, gene promoters) as has been suggested
previously [24; data not shown]. A cross-vali-
dation of the top differentially methylated
CpGs in the Hispanic and non-Hispanic white
subsets resulted in the replication of the top
two (cg19689947 in ZNF77 and cg02718229 in
EHD2; Table 2) as being consistently and sig-
nificantly less methylated in CL/P cases than in
controls (cross-validation p < 0.05 in both
groups).
Overall, CL/P-associated EWAS profiles dis-
played more significantly associated CpG sites
than expected by chance, as illustrated by the
left deviation of the p value histogram and the
upper deviation of the quantile-quantile (q-q)
Figure 1. Regression coefficients for 319,253 CpGs in the final, filtered analytical dataset are plotted versus p value (expressed as –
log10 p). Left panel: All samples (94 cases, 88 controls). Middle panel: Hispanic-only samples (74 cases, 69 controls). Right panel:
non-Hispanic white-only samples (20 cases, 19 controls).
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plot (Fig. S2). The q-q plot presented a general
inflation factor = 1.69 (based on median χ2).
For the top two CpGs, the p value corrected for
genomic inflation = 6.4E-05 (cg19689947) and
0.00012 (cg02718229).
Differentially methylated region (DMR) analysis
CpG sites in close proximity in the genome are often
highly correlated and tend to overlap functional ele-
ments. Therefore, differential methylation signals in
these regions may be more biologically relevant than
Table 2. The 28 differentially methylated positions meeting epigenome-wide significance (p = 1.57E-07).
CpG ID Chrom Position Associated Genea Regression Coefficient p value
Case
Avg
β val
Ctrl
Avg
β val Location in Geneb
cg19689947 19 2941933 ZNF77 −0.173 7.08E-11 0.782 0.804 Body
cg02718229 19 48230862 EHD2 −0.160 3.32E-10 0.831 0.849 Body
cg13113642 17 997200 ABR −0.163 1.97E-09 0.913 0.924 Body
cg00401471 19 38782834 SPINT2 −0.183 3.32E-09 0.718 0.746 3ʹUTR
cg17399234 5 110428454 WDR36 −0.133 4.48E-09 0.066 0.076 Body
cg27052183 11 66411986 RBM4 −0.150 4.78E-09 0.827 0.842 3ʹUTR
cg22906451 19 1994824 BTBD2 −0.132 6.03E-09 0.843 0.857 Body
cg24007247 7 6410669 −0.138 8.42E-09 0.869 0.882
cg05911749 16 30956151 FBXL19 −0.096 1.02E-08 0.906 0.912 Body
cg22726273 8 145268244 HEATR7A −0.121 1.28E-08 0.886 0.896 3ʹUTR
cg23072571 19 54291978 MIR373 −0.154 1.45E-08 0.804 0.822 Body
cg15471981 19 54291942 MIR373 −0.138 2.05E-08 0.853 0.865 TSS200
cg15089892 3 101568188 NFKBIZ −0.113 2.13E-08 0.029 0.032 5ʹUTR
cg07805699 3 159481815 SCHIP1 −0.111 2.66E-08 0.047 0.052 Body
cg15333818 12 46766724 SLC38A2 −0.113 2.94E-08 0.051 0.057 TSS200
cg09610578 3 129407542 TMCC1 −0.122 3.16E-08 0.828 0.838 TSS200
cg11855842 1 23807492 ASAP3 −0.141 3.65E-08 0.883 0.895 Body
cg20801637 1 1795408 GNB1 −0.126 3.67E-08 0.822 0.837 5ʹUTR
cg02466815 2 177054573 HOXD1 −0.150 3.71E-08 0.083 0.093 Body
cg23987548 17 73401912 GRB2 −0.106 3.82E-08 0.025 0.027 TSS200
cg11390978 19 16986831 SIN3B −0.150 3.87E-08 0.870 0.885 Body
cg05612966 5 95583220 −0.209 5.57E-08 0.915 0.931
cg24406116 1 109940036 SORT1 −0.093 8.17E-08 0.040 0.043 Body
cg10057318 1 91966336 CDC7 −0.115 8.38E-08 0.069 0.077 TSS1500
cg25137403 2 177022172 −0.111 9.56E-08 0.036 0.039
cg07779777 19 4047755 ZBTB7A −0.150 9.83E-08 0.891 0.903 Body
cg14125003 11 67978396 SUV420H1 −0.127 1.18E-07 0.837 0.852 5ʹUTR
cg02756655 2 65663632 −0.148 1.53E-07 0.241 0.266
a According to UCSC genome browser via Illumina Genome Studio software
b Gene-associated CpGs are localized to gene body (between start/stop codons, including introns), untranslated regions (UTR), and upstream
proximity (kb) to the transcription start site (TSS).
Figure 2. Directional concordance of regression coefficients between Hispanic and non-Hispanic white sample sets for subsets of
CpG sites. The numbers of CpG sites in each quadrant are indicated. Left panel: All 319,253 CpG in the analytical dataset. Middle
panel: 2,694 CpG sites with p value < 0.05 in both sample sets. Right panel: 262 CpG sites with p value < 0.01 in both sample sets.
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individual CpGs. The most significantly CL/
P-associated DMRs are described in Table S4. The
most significant association was seen for the gene
region surrounding the small, non-coding RNA
VTRNA2-1, which was significantly less methylated
in CL/P cases (Figure 3). This was the sole DMR that
remained significant following correction for multi-
ple testing (FWER p value = 0.014 for the entire
population). In support of this finding, we per-
formed 100 bump hunting analyses following per-
mutation of the case/control variable; 87 identified
VTRNA2-1 as a DMR resulting in a permutation-
based corrected p value of 0.02 (initial p value ranked
2nd over 100).
In analyses following ethnic stratification, the
VTRNA2-1 region was also the most significantly
associated DMR in both Hispanics and non-
Hispanic whites, though in neither case did the
significance survive the FWER-correction for mul-
tiple testing (Table S4). Sensitivity analyses in all
participants and in stratified sub-populations pro-
duced similar results with VTRNA2-1 consistently
presenting as one of the most significantly CL/
P-associated DMRs, independent of the para-
meters of the bump hunting function (Table S5).
Interestingly, a survey of the top DMRs in Tables
S4 and S5 does not indicate a similarly strong
trend toward case hypomethylation as was seen
from individual CpG sties in EWAS analysis. The
significance of this is discussed below.
Metastable epiallele regions and disease risk
The appearance of theVTRNA2-1 region as the most
significant DMR associated with CL/P is notable
since this CpG-rich segment has been previously
characterized as a ‘metastable epiallele’ [20].
Metastable epialleles are regions whose methylation
states are established in early embryogenesis and are
sensitive to periconceptional environment, particu-
larly maternal nutrition status [20-22]. Since mater-
nal periconceptional intake of folate and choline,
both of which contribute to the synthesis of methyl
donors necessary for DNAmethylation, canmitigate
risk for CL/P, it is plausible that epigenomic regions
sensitive to in utero environment in early embryo-
genesis (i.e. metastable epialleles) may contribute to
disease risk. Although VTRNA2-1 has yet to be
implicated in CL/P risk, a role is still formally possi-
ble. Alternatively, changes at this locus may simply
be a sentinel reflecting more widespread metastable
epiallele-related changes, in general, in newborn case
epigenomes. In support of this hypothesis, we
observed a trend of greater case-associated DNA
methylation changes at CpG sites near putative
metastable allele regions (Figure 4, Figure S4).
Metastable epiallele regions in the epigenome have
thus far been defined based on CpG clusters with
inter-individual variability and systemic intra-
individual similarity [20,21]. We observed that the
average magnitude of CL/P-associated methylation
changes for array CpGs (both positive and negative
Figure 3. Distributions of DNA methylation β-values for each of the 12 CpG sites (identified by chromosomal coordinate) within the
~1 kb region surrounding the VTRNA2-1 gene. Data is from all cases (N = 94, gray-filled boxes) and all controls (N = 88, white-filled
boxes). VTRNA2-1 transcript coordinates are chr5:135416187–135416286.
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as measured by the absolute value of the regression
coefficient) increased significantly based on nearness
to these metastable epiallele regions (Figure 4; refer-
ence dataset was table S2 in ref. 20 defining 4,853
200bp genomic segments with metastable epiallele
characteristics). In the same study, these authors also
define a more discernible subset of putative epialleles
(N = 109) with dense CpG clustering (Fig. S4a), and
a recent study [21] further defined 687 epigenome-
wide metastable regions with different clustering/
length criteria (Fig. S4b). Using any of these 3 data-
sets as reference, we saw a significantly greater extent
of methylation changes at or near metastable epial-
lele regions in general. Furthermore, besides
VTRNA2-1, two additional CL/P-associated DMRs
(PAX8-AS1, chr 2; ZFP57, chr6; Table S5) overlap
metastable epialleles whose methylation levels are
influenced by season of conception in populations
where maternal nutrient availability varies widely by
season [20]. Thus, some of the strongest CL/
P-associated DNA methylation changes occurred at
epigenomic regions known to be sensitive to peri-
conceptional environment.
Gene set enrichment analysis
To understand the link between methylation
changes at cleft-associated DMRs or individual
CpGs, and how these might be implicated in disease
risk, we performed Gene Set Enrichment Analysis of
associated genes (see Methods). The geneset high-
lighted by DMRs displayed significant enrichment
for processes involved in craniofacial development,
palatogenesis and clefting. Although VTRNA2-1 was
the only DMR to maintain significance following
FWER multiple comparison corrections, the bump-
hunting analysis identified a total of 472 CL/
P-associated DMRs encompassing 427 genes with
p values ranging from 5E-06 to 0.08. Some DMRs
from this analysis were nearby or adjacent, thus
multiple DMRs highlight the same region and asso-
ciated gene. All DMRs were considered in this ana-
lysis regardless of p value (geneset in Table S6).
Function enrichment queries with this unfiltered
gene set returned nominally significant enrichments
(p < 0.05) for relevant processes/functions (Table S7)
such as genes implicated in Head Development
(p = 1.3E-04), Cleft Lip (p = 8.7E-03), and Midline
Defects (p = 7.9E-03). Thus, these analyses suggested
that relevant biological processes may be affected by
CL/P-associated methylation changes that may pro-
vide at least some of the mechanistic link underlying
the nutritional modification of CL/P risk.
In contrast, the genes associated with individual
CpGs displaying genome-wide significance in
EWAS analysis (Table 2) show no significant enrich-
ment of relevant developmental processes, nor have
any been previously implicated in orofacial cleft risk
or palatogenesis. Expanding the relevant gene set to
identify cleft-related signals by considering highly
ranked sites that fell short of genome-wide signifi-
cance (e.g. top 500 CpGs), similarly showed no func-
tional enrichment in processes related to craniofacial
development or dysmorphology.
Orofacial cleft-relevant DMRs
Overall, the bump hunting analyses revealed 10
DMR-linked genes with evidence for their involve-
ment in CL/P risk (Table 3). These genes have been
implicated in clefting by either human genetic asso-
ciation studies, or by their roles in palatogenesis and/
or cleft development in vertebrate model organisms.
Although the biological impact of altered methyla-
tion patterns at these sites is unknown, there were
several noteworthy DMRs that occurred at or near
the transcription start sites for their respective genes
Figure 4. All CpGs were binned based on proximity (kb) to
putative metastable epiallele regions as defined and localized
in Table S2 from ref. 20. For each distance bin shown in the
figure, the average extent of case-associated methylation
changes were calculated by averaging the absolute value of
the regression coefficients (to equally account for hypo- and
hypermethylation events). # CpGs averaged per bin is indicated.
A distance of ‘0’ indicates CpGs that fall within the borders of
a metastable epiallele region. Significance of pair-wise distribu-
tion comparisons was determined by the Mann Whitney U test.
* p < .05; ** p < 0.005; *** p < 0.0005.
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(Figure 5). Measuring the difference in mean beta
values (i.e. the fraction of methylated sites) between
cases and controls, we observed a DMRhypermethy-
lated in cases surrounding the transcription start site
of the microRNA MIR140 (Figure 5, top panel),
which has been implicated in orofacial cleft risk
and palatogenesis in both humans [25] and zebrafish
[26]. We also observed a region of case hypermethy-
lation in the promoter of WNT9B, a signaling pro-
tein influencing embryonic development and
implicated in cleft risk based on a murine model
[14]. Figure 5 (bottom panel) also shows a DMR
hypomethylated in CL/P cases that overlaps a CpG
island, DNaseI hypersensitive clusters and binding
sites for multiple transcription factors, ~ 2.8kb
upstream of the LHX8 TSS. Deletion of LHX8,
a homeobox member transcription factor, results in
a cleft palate phenotype in lhx8-mutant mice [27].
Interestingly, the DMRs associated with the set of
10 CL/P-related genes (Table 3) are more likely to
be near putative metastable epiallele regions than
other DMRs identified (Figure S5). When com-
pared against other DMRs near other genes (either
those implicated in craniofacial development but
not obviously related to clefts (N = 45), or those
not annotated as craniofacially related (N = 372)),
this set of 10 was significantly more enriched for
regions within 100, 50 and 10kb of putative meta-
stable epiallele regions, using the same reference
dataset as that in Figure 4. However, it should be
noted that we did not see the same enrichment for
epiallele proximity using the metastable epiallele
regions defined in ref. 21. Thus, while providing
further evidence for the implication of metastable
epiallele regions in cleft risk, the significance of
these results await further study.
Discussion
Weexplored the possiblemechanismbywhichmater-
nal periconceptional folic acid intake reduces risk for
offspring with isolated orofacial clefts by investigating
fetal DNA methylation changes at birth. To that end,
we measured methylation levels in newborns at indi-
vidual CpG sites or at loci where clustered CpG sites
behaved coordinately to define a Differentially
Methylated Region (DMR). We restricted analysis to
only births that occurred prior to mandatory dietary
folate fortification in theUnited States (birth year 1997
or earlier) with the expectation that, in the absence of
widespread dietary fortification, the case-control dif-
ferential in folate intake might be more significant
and, therefore, folate-related events would be easier
to observe. Our focus on pre-fortification births is
supported by the observation that rates of occurrence
of isolated orofacial clefs in California decreased in the
post-fortification period [28]. In this population, CL/P
case newborns displayed a striking epigenome-wide
Table 3. Ten differentially methylated regions that contain at least 2 nearby CpGs and are closely associated with genes implicated
in orofacial clefts.
Chromosome Start DMR length # CpG in DMR Value p valuea Nearest Gene mRNA RefSeq Location in Geneb Referencec
16 69966902 161 4 0.043 0.017 MIR140 NR029681 TSS overlap 25,26
1 75590912 442 4 −0.034 0.046 LHX8 NM001001933 TSS −2766 27
1 3239916 312 3 0.029 0.021 PRDM16 NM022114 Intron 3,
TSS +254174
46
17 44928210 307 3 0.034 0.042 WNT9B NM003396 Promoter,
TSS −451
14,47
1 164545553 147 3 −0.034 0.044 PBX1 NM002585 Intron 2,
TSS +16956
48
16 84860766 152 3 0.030 0.045 CRISPLD2 NM031476 Intron 1,
TSS +7179
49
14 95330880 105 2 0.031 0.058 GSC NM173849 Intergenic,
TSS −94381
50
14 54418728 77 2 −0.03 0.067 BMP4 NM001202 Exon 3,
TSS +4826
51,52
1 23279554 132 2 −0.028 0.074 EPHB2 NM004422 Intergenic,
TSS +242222
53
1 12656232 84 2 0.026 0.082 DHRS3 NM004753 Intron 1,
TSS +21504
54
a Uncorrected for multiple comparisons
b Gene feature location with distance (bp) upstream or downstream of the transcription start site (TSS)
c Reports that gene is associated with isolated orofacial clefts (human or vertebrate models) and/or palatogenesis.
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trend toward hypomethylation. Moreover, the most
extensive case-associated methylation changes
occurred at or near putative metastable epiallele
regions. CL/P-associated DMRs were near genes pre-
viously implicated to be involved in orofacial clefts
and/or palatogenesis.
Figure 5. The difference in mean β-values between CL/P cases relative to controls for the individual CpGs (delineated as
chromosomal coordinates) that comprise DMRs described in Table 3. Plots depict the DMR CpGs plus 6 adjacent CpGs that flank
the DMR on either end. Top panel: MIR140; transcription start site at coordinate 69966984. Middle panel: WNT9B promoter;
transcription start site at coordinate 44928968. Bottom panel: CpG island (Chr1:75590818–75591354) upstream of LHX8 transcrip-
tion start site (coordinate 75594119).
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We observed a fairly extensive hypomethylation
in CL/P cases: nearly two-thirds (63.5%) of the CpG
sites interrogated had lower methylation levels in
case newborns, a tendency which held up in racially
stratified sub-populations (61% in Hispanics, 62% in
non-Hispanic whites; Figure 1). Furthermore, the
most significantly CL/P-associated sites were heavily
skewed toward hypomethylation: the 28 CpG sites
that reached epigenome-wide significance in EWAS
analysis all had lower methylation levels in cases
(Table 2). Indeed, this trend was present throughout
the methylation profile even for sites with nominal
p values. For example, 78% of CpG sites with p value
< 0.05 (total N = 41,429) had lower methylation
levels in cases, as did 74% of CpG sites with p value
< 0.2 (total N = 102,312). These trends are seen
equally well in each ethnic sub-group. Indeed, sites
with greater significance in both sub-populations are
predominantly hypomethylated (Figure 2).
It is tempting to postulate that such a widespread
decrease in DNA methylation levels in CL/P cases
reflects exposure to a limiting amount of methyl
donors, which result from folate (or other 1-carbon-
related metabolite) insufficiencies. Thus, CL/
P-associated DNAmethylation changes at nutrition-
ally-sensitive epigenomic loci may partly explain the
mechanism by which orofacial cleft risk is responsive
to maternal folate supplementation, particularly if
such changes affect genes involved in craniofacial
development. However, the relationship between
maternal folate intakes and epigenetic patterning in
offspring is not necessarily a straightforward one, as
evidenced by epigenome-wide studies. For example,
Gonseth et al [29] observed an inverse correlation
between periconceptional folate supplementation
and methylation in newborns in that mostly hypo-
methylation events were observed with increasing
maternal folate intake. This trend, though counter-
intuitive, is consistent with observations made on
methylation sites in newborn DNA that associate
with maternal plasma folate levels during pregnancy
[30] andwithin offspringDMRs associated with low-
and high-dose maternal folate supplementation [31].
Nevertheless, different experimental designs in
these studies make it difficult to generalize the rela-
tionship betweenmaternal folate levels and fetal DNA
methylation. For example, Amerasekera et al [32]
identified 7 newborn DMRs significantly hypo- or
hyper-methylated relative to maternal serum folate
levels during the 3rd trimester of pregnancy.
However, at 5 of these loci, Gonseth et al [29]
observed the opposite directional effects with respect
to maternal periconceptional folate intakes. Two of
these regions were identified as CL/P-associated
DMRs in this study (ZFP57, chr6:29,648,507–623;
FZD7, chr2:202,901,352–428) where their methyla-
tion status indicated lower periconceptional folate
exposure in cases [according to the results of ref. 29].
While some of these inconsistencies can be
attributed to ascertaining folate levels at different
times during pregnancy (i.e. early vs. late), ascrib-
ing methylation changes to a single folate exposure
variable may capture only a portion of the relevant
nutritional information. For example, maternal
vitamin B12 levels can influence infant global
and site-specific DNA methylation patterns, pos-
sibly through its role as cofactor in the Methionine
Synthase (MTR) reaction necessary for AdoMet
synthesis [33]. In addition, choline is an essential
micronutrient involved in one-carbon metabolism
whose oxidative derivative, betaine, also converts
homocysteine to methionine, which provides an
additional synthetic route for AdoMet. Thus, mul-
tiple nutritional inputs (and their interaction)
probably contribute toward setting fetal epige-
nomic programming. Importantly, maternal levels
of vitamin B12 and choline have been implicated
in risk of CL/P in offspring [5,17,34].
The most significantly CL/P-associated DMR was
the region encompassing theVTRNA2-1 gene, which
was hypomethylated in cases (Figure 3). This CpG-
rich locus has been previously characterized as
a nutritionally-responsive, metastable epiallele
[20,31]. Silver et al [20] examined DNA methylation
profiles in infants in Gambia, where seasonality is
linked to significant differences in maternal diet, and
found thatVTRNA2-1methylation levels in offspring
positively correlated with maternal serum folate
levels in the season of conception. On the other
hand, Richmond et al [31] found an inverse correla-
tion of methylation levels at VTRNA2-1 in adult
children and pre-natal maternal folic acid supple-
mentation, but only at very high doses of folate
supplementation (5 mg/day).
As part of the explanation for the complex nature of
the relationship betweenmaternal folate and newborn
methylation, Gonseth et al [29] suggested that the fetal
epigenomic response to periconceptional folate intake
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may be bi-phasic. Their analyses, when stratified by
maternal folate status, indicated a positive correlation
between newborn methylation levels and folate intake
in births from folate-insufficient mothers (consump-
tion of <200 µg/d), whereas negative correlations
become more pronounced with higher folate intakes.
They hypothesize that folate may be limiting for DNA
methylation below a certain threshold, while increas-
ing folate in folate-replete populations may produce
compensatory or negative feedback effects. In this
regard, the population used in the current study,
which examines a stark folate-sensitive clinical pheno-
type in a pre-fortification population, may accentuate
effects of folate-limiting conditions.
Along with the widespread hypomethylation
changes, we also observed a significant genomic
inflation on the q-q plots indicatingmore statistically
significant case-control differences across the epi-
genome than expected (Fig. S2). This may be due
to unaccounted population substructure (e.g. from
a genetically admixed subpopulation of Hispanic
participants) or it may result from a global effect of
an environmental factor on DNA methylation, such
as folate intake. We believe that the latter is more
probable since genomic inflations have been com-
monly observed in previous studies determining the
impact of maternal folate levels on offspring DNA
methylation states [29-31]. This, in fact, may be
expected since it seems reasonable to assume that
under such conditions, much of the epigenome may
be affected.
Our results point toward metastable epialleles as
regions that epigenetically distinguish CL/P cases
from nonmalformed controls. Because epigenetic
programming at metastable epialleles and risk for
CL/P intersect at periconceptional nutrition status,
particularly nutrients involved in one-carbon
metabolism, they are logical candidates at which
to look for cleft-related signals. It is therefore
noteworthy that we observed: 1) several CL/
P-associated DMRs occurring at previously anno-
tated metastable epialleles (Figure 3, Table S4), 2)
the extent of methylation changes was greater at or
very near previously described metastable epiallele
regions (Figure 4, Fig. S4), and 3) Out of all CL/
P-associated DMRs, the most compelling candi-
dates were significantly closer to epiallelic loci
(Fig. S5). To make these claims, we have used
datasets from initial studies annotating metastable
epiallele regions in the human epigenome [20,21].
It is likely, however, that these regions will be
more comprehensively defined in future studies
and so it will be of particular interest to see if
these relationships are supported. It is worth not-
ing that metastable epialleles have also been impli-
cated as sites in offspring epigenomes that are
particularly sensitive to maternal folic acid supple-
mentation [31].
CL/P-associated DMRs were associated with
genes that were enriched for relevant functional
categories and highlighted 10 genes that have pre-
viously been implicated in orofacial clefts and/or
palatogenesis (Table 3,Table S7). In the absence of
direct measurement, it is difficult to predict the
effect of methylation events on gene expression,
especially since some transcription factors prefer
to bind methylated sites [35]. Nevertheless, there
were 2 DMRs that are particularly deserving of
attention. We detected a case-hypermethylated
region surrounding the transcription start site of
the microRNA MIR140 (Figure 5). MIR140 was
first implicated in orofacial cleft formation from
experiments in zebrafish demonstrating that altered
expression levels resulted in craniofacial abnormal-
ities (including cleft palate), through its role in
modulation of PDGFRA [26]. This relationship
was subsequently observed in murine cells where
MIR140 expression is reduced by environmental
smoke exposure [25,36]. Importantly, a human
polymorphism that affects MIR140 processing is
associated with CL/P [37] and shows a significant
interaction for CL/P risk with passive smoke expo-
sure in the first trimester [25]. We hypothesize that
environmental impacts of MIR140 expression,
which contribute to CL/P risk, could be mediated
via DNA methylation changes at the DMR reported
in this study.
We observed a second case-hypermethylated
region in the promoter of WNT9B (Figure 5),
a secreted protein essential for murine craniofacial
development and implicated in malformations
including CL/P [38]. The potential for DNA methy-
lation changes to affect WNT9B transcription
thereby leading to CL/P risk is reminiscent of
a murine model for isolated orofacial clefts with an
epigenetic basis [14]. In the A/WySn mouse strain,
a DNA retrotransposon of the IAP (intracisternal
A particle) family has inserted downstream of the
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Wnt9b gene and drives an anti-sense transcript that
interferes with Wnt9b transcription. The effect is
variable, based on the degree of methylation and
silencing of the IAP, in which embryos with the
lowest levels of Wnt9b transcript develop cleft lip.
Thus, the IAP appears to be acting as a metastable
epiallele. Although the mechanism in this particular
mouse model is one of antisense interference rather
than promoter function, it does demonstrate that
a decrease in WNT9B transcription can contribute
to CL/P risk. It is worth noting at this DMR, as well
as those at MIR140 and LHX8, may be specific for
orofacial clefts: none of these were observed in
a separate Neural Tube Defect case population
(also pre-fortification) when compared against the
same controls used in this study (manuscript in
preparation).
Recent studies have also interrogated DNA
methylation changes as part of the underlying
mechanism for orofacial cleft occurrence [23,24]. In
an effort to identify methylation changes that are
specific to cleft subtypes, Sharp et al [23] identified
DMRs in direct case:case comparisons (e.g. Cleft
Palate Only vs. Cleft Lip Only infants). The authors
found significant differences relative to each pheno-
typic subtype, with the most significant changes seen
when comparing infants with a cleft lip (CLO, CL/P)
to those without (CPO). Because this was not a case:
control design, results are somewhat difficult to com-
pare to those in the current study. Nevertheless, we
observed a significant overlap between these cleft lip-
specific DMRs (N = 268) and the CL/P-associated
DMRs reported here (N = 472): 14 DMRs co-
localized towithin 1kb, 12 of whichwere overlapping
(see Table S8 for details). Thus, some DMRs that
distinguish cleft lip from cleft palate are also observed
in this case-control study, though none of the asso-
ciated genes are obviously involved in craniofacial
development.
Alvizi et al [24] queried DNA methylation
changes at individual CpGs in a CL/P case-control
population of Brazilian children. These authors
found 578 significantly associated CpGs that were
enriched for functional regions of the genome (e.g.
promoters, DNaseI hypersensitive sites, etc.) and
developmentally important pathways, such as
WNT/β-catenin signaling. Furthermore, the major-
ity of these sites (N = 361; 62.3%) were case-
hypomethylated. Beyond this, however, individual
CpGs significantly associated in the Brazilian study
were strikingly discordant with data in the current
study at the same positions. At 420 sites (of the 578)
that overlap both studies 280 were hypomethylated
in Brazilian cases whereas we observed hypermethy-
lation at 279 sites (77% discordance; Fisher’s exact
p value = 1.4E-22). Furthermore, only 11 of these
sites were represented in the most significant 10,000
sites from our EWAS analysis and all were discor-
dant: 11/11 were hypermethylated in Brazilian case
children yet hypomethylated in our case newborns.
It is worth noting that Brazil adopted mandatory
folate fortification in 2004, thus folate status may
be a critical difference between these populations.
This raises the important question as to how epige-
netic changes affect disease risk in folate-limiting
versus folate-replete populations. Importantly, these
authors also presented evidence that promoter DNA
methylation at CDH1, a gene oftenmutated in famil-
ial cases of CL/P, can interact with genetic variation
atCDH1 in a way whereby decreased expressionmay
increase penetrance of pathogenic variants. It will be
of interest to see if this a more general mechanism
for the contribution of cleft-associated methylation
changes.
Limitations/strengths
The strengths of this study lie in the case-control
design and the inclusion of different ethnicities to
mitigate race/ethnic-specific differences, con-
ducted prior to mandatory folic acid fortification.
We have postulated that folate-sensitive events
may be more obvious during this time period
since the overall levels of folate intake were lower
and more susceptible to consequential insufficien-
cies. Furthermore, we have proven the effective-
ness of genome-scale methylation analysis starting
with a limiting quantity (≤ 35 ng) of gDNA from
newborn bloodspots archived up to 30 years.
The study also has several limitations. We ascer-
tained DNA methylation profiles from newborn
whole blood, with the expectation that informative
differences presumably occurring in developing oro-
facial tissues would be preserved in this lineage.
Although probable, especially at metastable epiallele
regions where DNA methylation levels are estab-
lished prior to cell differentiation, it is possible that
there may be additional or more pronounced
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changes in embryonic lip or palatal tissue. Indeed,
this may be the reason that the CL/P-associated
methylation signals pointed our attention toward
metastable epiallele regions. Previous epigenetic stu-
dies on orofacial cleft have established a correlation
between methylation patterns seen in postnatal
blood versus lip or palate tissue, particularly in dif-
ferentially methylated regions associated with this
phenotype [23,24]. The DMRs identified in these
and the current study suggest that bloodmethylation
patterns will reflect at least some of the clinically
relevant changes.
We also have no direct measurements of mater-
nal folate status in this population. We have
assumed that maternal folate status would be dif-
ferent between cases and controls and, based on
the epidemiology, would likely favor controls. The
observation of CL/P-associated DMRs at or near
metastable epiallele regions supports a case-
control nutritional difference, but may not allow
unequivocal assignment of lower folate status to
cases. Other nutrients that impinge on one-carbon
precursors, such as choline and vitamin B12, may
also underlie case-control differences in this popu-
lation. Alternatively, some methylation changes
may be influenced by local genetic variation
(methylation QTLs), though the widespread hypo-
methylation trends observed here argues against
localized genetic influences. Nevertheless, the
unequivocal implication of maternal folate status
in CL/P-associated epigenetic changes can only be
made with accompanying maternal folate mea-
surements or a comparison before/after dietary
folate fortification.
Lastly, although starting with low gDNA inputs is
adequate, this does result in a mild (yet measurable)
increase in variability at some loci [39]. This, com-
bined with a small sample size, may have generated
spurious associations or, more likely, underestimated
significant associations. Therefore, replication of these
results in a second, larger population is essential.
Methods
Study population
This case-control study included data on infants
delivered between 1988–97. The study included
live-born infants with isolated CL/P (cases;
N = 97) or without any structural malformation
(controls; N = 93). Case information was abstracted
from hospital reports and medical records following
established procedures by the California Birth
Defects Monitoring Program [40]. Each medical
record was further reviewed by a medical geneticist
(Edward Lammer, MD). Infants with trisomies
were ineligible. Nonmalformed controls were
selected randomly to represent the population
from which the cases were derived in selected coun-
ties and birth periods. This study, including the
collection and use of archived newborn bloodspots,
was approved by the California State Committee for
the Protection of Human Subjects as well as
Institutional Review Boards at Stanford University
and the University of California, Berkeley.
DNA methylation assay from archived
bloodspots
Genomic DNA (gDNA) from each case or control
newborn bloodspot was isolated from a single, sur-
gical punch (2mm dia.) using the QIAamp DNA
Micro kit (QIAGEN) according to the manufac-
turer, with a final column elution volume of 25 µl.
Average yield was 40 ng gDNA/punch. For each
sample, 30–35 ng gDNA were bisulfite converted
using the EpiTect Bisulfite kit (QIAGEN) and
eluted in 16 µl buffer EB. Four µl of eluate was
processed for epigenome-wide profiling on the
HumanMethylation450 BeadChip® array (Illumina)
as per manufacturer’s instructions. We have pre-
viously reported that this process is robust and
reproducible for profiling limiting starting quanti-
ties of bloodspot gDNA [39].
Data quality filtering
Array CpGs with detection p values > 0.01 in 15%
of samples were excluded from analysis. Likewise,
samples in which >15% of CpGs had detection
p values > 0.01 (of the 450k loci) were also
excluded. Two samples had mismatched reported
and predicted gender and were removed from the
analysis. In addition, cross-reactive, poor quality
and SNP-associated probes were removed from
the analysis [41]. The final analytical dataset was
comprised of 319,253 CpG sites queried in 94
mostly-Hispanic cleft cases and 88 controls (see
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Table 1 for population breakdown). Methylation
data pre-processing was performed according to
Fortin et al [42]. All genomic coordinates are
based on human genome hg19, build 37.
Epigenome-wide association analysis
Epigenome-wide association studies (EWAS) were
carried out to agnostically discover differentially
methylated CpG sites between case and control new-
borns. Linear regression models (by the function
‘lmfit’ in the ‘limma’ R package) were carried out,
with DNA methylation beta-values (normalized
into M-values) as the outcome, and case/control
status as the variable of interest. Adjustments were
made to account for the following potential con-
founding factors: 1) gestational age, 2) gender, 3)
estimated cell-mixture (by the Refactor method
which uses an unsupervised feature selection step
followed by a sparse principal component analysis
[43]), 4) an estimation of ancestry (by the
Epistructure method which uses the principal com-
ponents of CpG sites known to be influenced by
genetic variation [44]), 5) batch effects, and 6) eth-
nicity as reported on the birth certificates. The
lambda genomic inflation factor was calculated on
p values using the ‘estlambda’ function of the
‘GenABEL’ R package. T-statistics resulting from
the linear regressions were divided by the lambda
genomic inflation factor to obtain p values corrected
for multiple testing. The Bonferroni-corrected p -
= 1.57 × 10−7 was used as the genome-wide level of
statistical significance. Manhattan plots and quan-
tile-quantile (q-q) plots were drawn according to the
‘qqman’ R package. Additional analyses stratified by
ethnicity were carried out. Additionally 1,000 boot-
strap EWAS analyses were performed in both ethnic
groups separately to decrease potential influences of
outliers. Bootstrap-resulting p values were calculated
by taking the geometric mean of the distribution of
bootstrap p values for each association. A bootstrap
p value below 0.05 and a concordance in the direc-
tion of the association were the criteria that were
applied to cross-validate CL/P-associated sites.
Bump-hunting analysis
To discover differentially methylated regions (DMRs)
between cases and controls, we used bump-hunting
methods [45] and the corresponding function ‘bum-
phunter’ from the ‘bumphunter’ R package. We car-
ried out genome-wide bump hunting analysis in all
participants together, and also following ethnic strati-
fication, while settingDNAmethylation beta-values as
the outcome and case/control status as the variable of
interest. The same adjustments were made as for
EWAS analysis. A thousand bootstraps were per-
formed to calculate Family-Wise Error Rate (FWER)
p values within the ‘bumphunter’ function. The
maxGap (i.e., number of base pairs to include in
a ‘bump’) was set at 500. Additional sensitivity ana-
lyses were performed by varyingmaxGap (250 to 2000
bp), and setting the smoothing function on/off.
Finally, we ranked the p value of the most associated
DMR against a distribution of p values generated
under the null by 100 bump hunting analyses while
making permutations of case/control status. The rank
of the original p value was divided by 100 to obtain
a permutation-based corrected p value. All statistical
analyses were performed using the statistical software
R, version 3.2.1.
Gene set enrichment analysis
To identify biologically relevant mechanisms (and
potential cleft risk genes) indicated by the differential
methylation data, we evaluated genes associated with
individual CpGs, as well as the DMRs defined in the
bump-hunting analyses. CpGs or DMRs were fil-
tered based on p value, overlap of functional ele-
ments (e.g. – promoter, first intron, etc.) and/or
nearness (bp) to putative metastable epiallele regions
as partially defined previously [20,21; see Results].
Associated genes were defined as those with tran-
scription start sites nearest the CpG or DMR of
interest. Enrichment of Gene Ontology (GO) or
pathway terms was determined using Ingenuity
Pathway Analysis (IPA, version #42012434, www.
qiagenbioinformatics.com).Within the IPA package,
Fisher’s exact test was used to measure the probabil-
ity that a category was randomly associated. In all
cases, terms/processes with p values for enrichment
< 0.05 were considered of interest. A second software
package (DAVID: Database for Annotation,
Visualization and Integrated Discovery, v6.8; www.
david.ncifcrf.gov) was also used primarily for verifi-
cation of the annotations and enrichments revealed
from the IPA analysis.
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